SCHEMBL25331985

SCHEMBL25331985

CC1COCC(c2ccc(Br)cc2)N1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGAT1 O75907 1/20 0.36
MAPT P10636 2/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
TDP1 Q9NUW8 2/20 0.36
ALDH1A1 P00352 3/20 0.35
CYP3A4 P08684 3/20 0.34
CYP2C9 P11712 3/20 0.34
CYP2C19 P33261 2/20 0.34
LMNA P02545 2/20 0.34
TAAR1 Q96RJ0 1/20 0.34
TSHR P16473 1/20 0.34
ALOX15 P16050 1/20 0.34
MAPK1 P28482 1/20 0.34
KDM1A O60341 5/20 0.33
KCNH2 Q12809 2/20 0.33
MAOB P27338 2/20 0.33
RCOR1 Q9UKL0 2/20 0.33
KDM1B Q8NB78 1/20 0.33
HPGD P15428 1/20 0.33
METTL3 Q86U44 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25331982 1.00 DGAT1 (0.36) DGAT1MAPTSMN1; SMN2TDP1ALDH1A1
SCHEMBL23123313 0.82 KDM1A (0.33) TDP1TSHRKDM1AKCNH2METTL3
SCHEMBL23123726 0.82 KDM1A (0.33) TDP1TSHRKDM1AKCNH2METTL3
SCHEMBL24700456 0.82 KDM1A (0.33) TDP1TSHRKDM1AKCNH2METTL3
SCHEMBL24700455 0.82 KDM1A (0.33) TDP1TSHRKDM1AKCNH2METTL3
SCHEMBL7294639 0.81 SMN1; SMN2 (0.41) SMN1; SMN2CYP2C19LMNATSHRMETTL3
SCHEMBL8128459 0.81 SMN1; SMN2 (0.41) SMN1; SMN2CYP2C19LMNATSHRMETTL3
SCHEMBL23522761 0.78 HTR2C (0.40) MAPTALDH1A1KDM1AMAOBRCOR1
SCHEMBL24540920 0.78 HTR2C (0.40) MAPTALDH1A1KDM1AMAOBRCOR1
SCHEMBL23522762 0.78 HTR2C (0.40) MAPTALDH1A1KDM1AMAOBRCOR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122223-A1 HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS ALMAC DISCOVERY LIMITED (GB) 2025-04-17 US disclosed
EP-4466072-A1 HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS Almac Discovery Limited (GB) 2024-11-27 EP disclosed
WO-2023139241-A1 HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS ALMAC DISCOVERY LIMITED (GB) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122223-A1 HETEROCYCLIC COMPOUNDS AS UBIQUITIN SPECIFIC PROTEASE 7 INHIBITORS USP7, UBA7, SENP7 DGAT1 3996/4885MAPT 1011/4885SMN1; SMN2 3270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.